TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
Launched by TELIK · Jan 21, 2003
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- • Inclusion Criteria
- • Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube, or primary peritoneal cancer
- • Recurrent ovarian cancer or persistent disease following primary treatment
- • At least one, but no more than four, prior chemotherapy regimens (all platinum-containing counted as one)
- • At least 18 years of age
- • Exclusion Criteria
- • Pregnant or lactating women
- • History of prior malignancy except for adequately treated carcinoma in situ of the uterine cervix, basal cell or squamous cell skin cancer, or other cancer for which patient has been disease-free for at least 2 years
- • Known leptomeningeal metastases or carcinomatous meningitis
- • Having received whole pelvis radiation therapy
About Telik
Telik, a biopharmaceutical company, focuses on the discovery and development of innovative therapies for cancer and other serious diseases. Leveraging its proprietary drug development platform, Telik aims to identify and advance novel compounds that target critical pathways in tumor biology. With a commitment to scientific excellence and patient-centric approaches, the company strives to bring transformative treatments to market, addressing unmet medical needs and improving the quality of life for patients worldwide. Through rigorous clinical trials and collaborations, Telik is dedicated to fostering advancements in therapeutic options and enhancing outcomes in oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Skokie, Illinois, United States
Boston, Massachusetts, United States
Houston, Texas, United States
Santa Monica, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials